/
PRGO
$10.05+$0.10 (+1.01%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.4B
138M shares
52-week range
$9.23 – $28.44
4% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Borrow rate
0.42%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-36.66
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.73B | $3.87B | $4.09B | $4.14B | $4.45B | $4.66B | $4.37B | $4.25B |
| Cost of revenue | $2.90B | $2.44B | $2.59B | $2.72B | $3.00B | $2.98B | $2.83B | $2.76B |
| Gross profit | $1.83B | $1.43B | $1.49B | $1.42B | $1.46B | $1.68B | $1.54B | $1.49B |
| Gross margin | 38.7% | 37.0% | 36.6% | 34.2% | 32.7% | 36.1% | 35.3% | 35.1% |
| R&D | $218.6M | $119.2M | $121.7M | $122.0M | $123.1M | $122.5M | $112.2M | $95.4M |
| Operating income | $236.5M | $174.7M | $265.2M | $410.4M | $78.9M | $151.9M | $112.9M | $343.3M |
| EBITDA | $906.0M | $662.0M | $518.4M | $695.9M | $355.5M | $525.0M | $433.0M | −$797.9M |
| Net income | $131.0M | $146.1M | −$162.6M | −$68.9M | −$140.6M | −$12.7M | −$171.8M | −$1.43B |
| Net margin | 2.8% | 3.8% | -4.0% | -1.7% | -3.2% | -0.3% | -3.9% | -33.5% |
| EPS (diluted) | 0.95 | 1.07 | -1.19 | -0.98 | -0.97 | -0.09 | -1.25 | -10.29 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4.1B | $2.12 | $2.08–$2.16 | 3 |
| 2027 | $4.1B | $2.37 | $2.27–$2.46 | 3 |
| 2028 | $4.2B | $2.67 | $2.63–$2.73 | 1 |
| 2029 | $4.1B | $2.81 | $2.77–$2.86 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$582.85
Price
$10.05
Implied upside
+5699%
Peer comparison
PERRIGO COMPANY PLC
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
www.perrigo.com- Employees
- 8,100
- IPO / List date
- Dec 16, 1991
- HQ
- DUBLIN 2, L2
Held by traders on TradeandTell
No one on the platform currently holds PRGO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in PRGO as of their last filing.
Insider activity (SEC Form 4)
Dividend history
TTM yield · 11.54% ($1.16/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-29 | $0.2900 | 2026-06-16 |
| 2026-03-02 | $0.2900 | 2026-03-24 |
| 2025-11-28 | $0.2900 | 2025-12-16 |
| 2025-08-29 | $0.2900 | 2025-09-16 |
| 2025-05-30 | $0.2900 | 2025-06-17 |
| 2025-03-07 | $0.2900 | 2025-03-25 |
| 2024-11-29 | $0.2760 | 2024-12-17 |
| 2024-08-30 | $0.2760 | 2024-09-17 |
| 2024-05-31 | $0.2760 | 2024-06-18 |
| 2024-03-07 | $0.2760 | 2024-03-26 |
Recent trades on TradeandTell
No one on the platform has traded PRGO yet.
